Targepeutics Receives Grant from Caroline’s P.E.A.C.H. Foundation to Advance GB13 Development and Clinical Trials for DIPG/DMG

Targepeutics is honored to announce that it has received a grant from Caroline’s P.E.A.C.H. Foundation to support certain clinical trial expenses for GB13, an investigational therapy being developed for patients with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG).

This generous grant represents an important investment in advancing research and developing new therapeutic approaches for patients facing these devastating pediatric brain cancers.

DIPG and DMG remain among the most challenging pediatric cancer diagnoses, with a significant unmet need for effective treatment options. At Targepeutics, we are committed to advancing innovative therapeutic strategies and moving promising science forward through continued development and clinical investigation.

The support of Caroline’s P.E.A.C.H. Foundation will contribute to our ongoing efforts to advance GB13 and its clinical development. We are deeply grateful for the Foundation’s partnership, generosity, and dedication to supporting research that has the potential to make a difference in the lives of children and families affected by DIPG/DMG.

Caroline’s P.E.A.C.H. Foundation and Targepeutics share a common vision: a future where children diagnosed with these devastating diseases have more treatment options and greater hope.

We recognize that progress requires collaboration, commitment, and the support of organizations willing to invest in the future of research. We are proud to work alongside Caroline’s P.E.A.C.H. Foundation as we continue this important journey.

We are grateful for their belief in our work and remain focused on advancing GB13 for the patients and families who need new options.